drugset
drugset / Trial / NCT00311766

A Phase 2 Study on Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa

NCT00311766 ↗

Phase 2 Terminated 30 enrolled RegeneRx Biopharmaceuticals, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to investigate a treatment to enhance the healing of acute and chronic nonhealing cutaneous wounds, such as the erosions experienced by patients with Epidermolysis Bullosa (EB), by the known activity of thymosin beta 4 (Tβ4). Funding Source - FDA Office of Orphan Product Development (OOPD).

Timeline

Start
2006-02
Primary completion
2010-07
Completion
2012-11

Outcome

Outcome not reported

Stopped: “Lack of patient availability and expiration of study drug”

Drugs

EvaluationDrugModalityDoseRoute
Comparator Thymosin Beta 4 Peptide 0.01 % Topical
Comparator Thymosin Beta 4 Peptide 0.03 % Topical
Comparator Thymosin Beta 4 Peptide 0.1 % Topical

Indications

epidermolysis bullosa